Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyclosporine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA known ✓ | P62937 | 5/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 13/20 | 1.00 |
| ▸ | PPP3CA | Q08209 | 3/20 | 1.00 |
| ▸ | FKBP1B | P68106 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | TACR2 | P21452 | 1/20 | 1.00 |
| ▸ | PPIB | P23284 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclosporine SCHEMBL21170318 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| SCHEMBL23382247 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239446 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24224445 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL25083206 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239035 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL23192320 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| SCHEMBL23110210 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL24239036 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 | |
| Cyclosporine SCHEMBL23192319 | 1.00 | ABCB1 (1.00) | ABCB1PPIAPPP3CAFKBP1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 31454 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| WO-2026107085-A1 | METHODS OF TREATING LUPUS WITH CD19-CD20 DUAL CAR-T CELLS | GENENTECH, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137558-A1 | OPHTHALMIC DEVICE | Able Tx Ltd. (IL) | 2026-05-21 | — | — | US | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-20260125770-A1 | INFLAMMATORY DISORDER IN A FELIDAE | MARS, INCORPORATED (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260103532-A1 | PHARMACEUTICAL COMPOSITIONS OF HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF | KINIKSA PHARMACEUTICALS GMBH (CH) | 2026-04-16 | — | — | US | claimed |
| US-20260102373-A1 | LYMPH DIRECTING PRODRUGS | MONASH UNIVERSITY (AU) | 2026-04-16 | — | — | US | claimed |
| EP-0561772-A1 | A new pharmaceutical use of fusidic acid and derivatives thereof | BENDTZEN, Klaus (DK) | 1993-09-29 | — | — | EP | claimed |
| EP-0296122-B1 | CYCLOSPORINS AND THEIR USE AS PHARMACEUTICALS | SANDOZ AG (CH) | 1993-09-29 | — | — | EP | claimed |
| WO-1993017039-A1 | ISO-CYCLOSPORIN SALTS | SANDOZ LTD. (CH) | 1993-09-02 | — | — | WO | claimed |
| EP-0539319-A2 | Pharmaceutical cyclosporin composition | SANDOZ LTD. (CH) | 1993-04-28 | — | — | EP | claimed |
| EP-0504760-A1 | Ciclosporin form for pulmonary administration | SANDOZ LTD. (CH) | 1992-09-23 | — | — | EP | claimed |
| CN-1053010-A | PHARMACEUTICAL PREPARATION | PUETTER MEDICE CHEM PHARM (DE) | 1991-07-17 | — | — | CN | claimed |
| CN-1051503-A | Disease and treatment of diseases | NORPHARMCO INC (CA) | 1991-05-22 | — | — | CN | claimed |
| EP-0414632-A2 | Cyclosporin derivatives | SANDOZ LTD. (CH) | 1991-02-27 | — | — | EP | claimed |
| WO-1990004398-A1 | A NEW PHARMACEUTICAL USE OF FUSIDIC ACID AND DERIVATIVES THEREOF | BENDTZEN KLAUS (DK) | 1990-05-03 | — | — | WO | claimed |
| EP-0296122-A2 | Cyclosporins and their use as pharmaceuticals | SANDOZ AG (CH) | 1988-12-21 | — | — | EP | claimed |